Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference9 articles.
1. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials;Clément;Lancet Diabetes Endocrinol,2020
2. Proopiomelanocortin deficiency treated with a melanocortin-4receptor agonist;Kühnen;N Engl J Med,2016
3. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency;Clement;Nat Med,2018
4. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome;Haws;Diabetes Obes Metab,2020
5. Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment;Ayers;J Clin Endocrinol Metab,2018
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献